Glass flakes prompt two American Regent recalls

Glass delamination is being cited as the reason for two more drug recalls. American Regent is taking back one lot of cyanide-poisoning treatment sodium thiosulfate and one lot of intravenous-fluid supplement potassium phosphates injection. Both are packaged in vials and made by the drug distributor's parent, Luitpold Pharmaceuticals, owned by Daiichi Sankyo.

The sodium thiosulfate recall is for 10-mL vials while the potassium phosphates recall involves 5-mL units. Both recalls, announced late last week, reach the user level.

Delamination yields glass particle contamination. It has been the cause now of seven parenteral recalls, according to industry group Rx-360. Among them is another American Regent recall from late December of single-dose vials of sodium bicarbonate. Causes may include chemicals used in glass processing and drug formulation characteristics.

- see the American Regent announcement

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.